Vimarsana
Biggest News Aggregation in the World

Page 3 - World Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from World Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In World Dynamix Today - Breaking & Trending Today

Major Shifts in Management of Patients with Lupus Nephritis Spurred by Availability of Aurinia Pharmaceutical's Lupkynis and GSK's Benlysta, According to Spherix Global Insights - Vimarsana News

Major Shifts in Management of Patients with Lupus Nephritis Spurred by Availability of Aurinia Pharmaceutical's Lupkynis and GSK's Benlysta, According to Spherix Global Insights

/PRNewswire/ -- With the approvals of GlaxoSmithKline's Benlysta (belimumab) in lupus nephritis (LN) at the end of 2020 and Aurinia's Lupkynis (voclosporin) at...

Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech's Vabysmo Rising, Regeneron's Eylea and Genentech's Off-Label Avastin Remain Strong, According to Spherix Global Insights - Vimarsana News

Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech's Vabysmo Rising, Regeneron's Eylea and Genentech's Off-Label Avastin Remain Strong, According to Spherix Global Insights

/PRNewswire/ -- The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherix's RealWorld...

FibroGen/Astellas' EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, according to Spherix Global Insights - Vimarsana News

FibroGen/Astellas' EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, according to Spherix Global Insights

/PRNewswire/ -- After a regulatory debacle in the United States which ended with FibroGen and AstraZeneca receiving a Complete Response Letter in August 2021...

FibroGen/Astellas' EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, according to Spherix Global Insights - Vimarsana News

FibroGen/Astellas' EVRENZO (roxadustat) Gaining Traction in the United Kingdom and Germany, according to Spherix Global Insights

/PRNewswire/ -- After a regulatory debacle in the United States which ended with FibroGen and AstraZeneca receiving a Complete Response Letter in August 2021...

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports - Vimarsana News

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports

/PRNewswire/ -- US gastroenterologists estimate that just under 60% of their ulcerative colitis (UC) and 55% of their Crohn's disease (CD) patients treated...